---
title: "Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281092566.md"
description: "OLN324 has shown significantly quicker and more substantial enhancements in anatomic results in patients with diabetic macular edema (DME), along with slightly higher visual improvements that were maintained throughout 20 weeks. This was achieved with fewer follow-up treatments when compared to faricimab. Recent anatomical data indicates that OLN324 effectively achieves faster, greater, and longer-lasting improvements in DME patients."
datetime: "2026-03-31T00:02:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281092566.md)
  - [en](https://longbridge.com/en/news/281092566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281092566.md)
---

# Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema

OLN324 has shown significantly quicker and more substantial enhancements in anatomic results in patients with diabetic macular edema (DME), along with slightly higher visual improvements that were maintained throughout 20 weeks. This was achieved with fewer follow-up treatments when compared to faricimab. Recent anatomical data indicates that OLN324 effectively achieves faster, greater, and longer-lasting improvements in DME patients.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [<![CDATA[FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer]]>](https://longbridge.com/en/news/288460866.md)
- [Roche Announces FDA's Filing Acceptance Under Priority Review For Giredestrant](https://longbridge.com/en/news/288370361.md)
- [EU clears PharmaMar’s Zepzelca combo for first‑line maintenance in aggressive lung cancer](https://longbridge.com/en/news/288437506.md)
- [A Look At BioMarin Pharmaceutical (BMRN) Valuation After Positive Voxzogo Phase 3 Trial Results](https://longbridge.com/en/news/287739403.md)
- [Roche Launches Liver Disease Panel To Help Clinicians Identify Risk Earlier](https://longbridge.com/en/news/287752950.md)